REG - Genflow Biosciences - Result of AGM

Genflow BiosciencesAnnouncement

12/06/2025 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250612:nRSL5872Ma&default-theme=true

RNS Number : 5872M  Genflow Biosciences PLC  12 June 2025

 

12 June 2025

Genflow Biosciences Plc

Results of Annual General Meeting

 

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company")
an emerging leader in the field of longevity research, focused on developing
therapeutic solutions for the prevention of age-related diseases is pleased to
announce that all resolutions proposed at the Annual General Meeting held
earlier today were duly passed by shareholders. The number of proxy votes for
each resolution submitted prior to the meeting are presented below.

 

Proxy Voting Results

 

 Ordinary Resolutions                                                          Votes for    % of votes cast for  Votes Against  % of votes cast against  Total votes cast  Votes withheld
 1. To receive and consider the Annual Report and Accounts for the year ended  152,365,311  99.5%                312            0.0%                     152,365,623       753,187
 31 December 2024 together with the Directors' Report and Auditors' Report

 thereon.
 2. To approve the directors' remuneration report for the financial period     152,069,752  99.3%                270,744        0.2%                     152,340,496       778,314
 ended 31 December 2024 set out in the audited accounts for the financial

 period ended 31 December 2024.
 3. To re-appoint PKF Littlejohn LLP as auditors of the Company and to         151,451,787  98.9%                121,889        0.1%                     151,573,676       1,545,134
 authorise the Directors of the Company to fix their remuneration.

 4. To re-elect Tamara Joseph as a Director of the Company.                    151,449,590  98.9%                206,583        0.1%                     151,656,173       1,462,637

 5. To re-elect Dr Guy-Charles Fanneau de La Horie as a Director of the        151,448,295  98.9%                207,469        0.1%                     151,655,764       1,463,046
 Company.

 6. To re-elect Dr Eric Leire as a Director of the Company.                    152,668,756  99.7%                192,686        0.1%                     152,861,442       257,368

 7. To re-elect Dr Yassine Bendiabdallah as a Director of the Company.         151,442,263  98.9%                213,734        0.1%                     151,655,997       1,462,813

 8. To re-elect Dr Peter King Lewis as a Director of the Company.              152,636,489  99.7%                192,843        0.1%                     152,829,332       289,478

 9. To authorise the Directors to allot shares in the Company.                 132,658,404  86.6%                19,655,616     12.8%                    152,314,020       804,790

 Special Resolution                                                            Votes for    % of votes cast for  Votes Against  % of votes cast against  Total votes cast  Votes withheld
 10. To disapply statutory pre-emption rights.                                 132,698,727  86.7%                18,861,048     12.3%                    151,559,775       1,559,035

 

 Contacts

                                   Harbor Access

 Genflow Biosciences
 Dr Eric Leire, CEO                Jonathan Paterson, Investor Relations
 +32-477-495-881                   +1 475 477 9401
                                   Jonathan.Paterson@Harbor-access.com

 Corporate Brokers
 Capital Plus Partners Ltd
 Jon Critchley, +44 0203 821 6168

 

About Genflow

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore
the potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments.

Please visit www.genflowbio.com (http://www.genflowbio.com) and follow the
Company on LinkedIn and Twitter/X.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPKBBDCBKKPAD